Wellington Management Group
IOVA icon

Wellington Management Group’s Iovance Biotherapeutics IOVA Stock Holding History

Wellington Management Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$531K Buy
+127,740
New +$485K ﹤0.01% 1824
2025
Q2 		– Sell
-119,008
Closed -$396K – 1993
2025
Q1 		$396K Buy
119,008
+1,582
+1% +$8.16K ﹤0.01% 1854
2024
Q4 		$869K Sell
117,426
-12,056
-9% -$112K ﹤0.01% 1741
2024
Q3 		$1.22M Buy
129,482
+12,064
+10% +$114K ﹤0.01% 1672
2024
Q2 		$942K Buy
117,418
+7,199
+7% +$77.1K ﹤0.01% 1688
2024
Q1 		$1.63M Sell
110,219
-44,926
-29% -$523K ﹤0.01% 1570
2023
Q4 		$1.26M Buy
155,145
+53,572
+53% +$280K ﹤0.01% 1581
2023
Q3 		$462K Sell
101,573
-27,627
-21% -$180K ﹤0.01% 1708
2023
Q2 		$910K Sell
129,200
-25,286
-16% -$181K ﹤0.01% 1618
2023
Q1 		$944K Sell
154,486
-267,124
-63% -$1.84M ﹤0.01% 1671
2022
Q4 		$2.69M Sell
421,610
-1,217,925
-74% -$9.51M ﹤0.01% 1433
2022
Q3 		$15.7M Buy
1,639,535
+305,473
+23% +$3.52M ﹤0.01% 984
2022
Q2 		$14.7M Sell
1,334,062
-9,954,664
-88% -$130M ﹤0.01% 1023
2022
Q1 		$188M Buy
11,288,726
+1,704,644
+18% +$26.4M 0.03% 430
2021
Q4 		$183M Buy
9,584,082
+684,552
+8% +$15.1M 0.03% 465
2021
Q3 		$219M Buy
8,899,530
+1,648,287
+23% +$38.8M 0.04% 418
2021
Q2 		$189M Buy
7,251,243
+3,586
+0% +$93.2K 0.03% 453
2021
Q1 		$229M Buy
7,247,657
+1,635,725
+29% +$67.8M 0.04% 394
2020
Q4 		$260M Buy
5,611,932
+4,964,622
+767% +$197M 0.05% 347
2020
Q3 		$21.3M Sell
647,310
-2,122
-0.3% -$65.1K ﹤0.01% 941
2020
Q2 		$17.8M Sell
649,432
-1,124,940
-63% -$37M ﹤0.01% 950
2020
Q1 		$53.1M Sell
1,774,372
-629,332
-26% -$16.7M 0.01% 621
2019
Q4 		$66.5M Buy
2,403,704
+1,255,069
+109% +$28.5M 0.01% 685
2019
Q3 		$20.9M Buy
1,148,635
+761,258
+197% +$16.8M ﹤0.01% 950
2019
Q2 		$9.5M Buy
+387,377
New +$5.83M ﹤0.01% 1230
2018
Q3 		– Sell
-63,237
Closed -$809K – 2259
2018
Q2 		$809K Sell
63,237
-8,548
-12% -$125K ﹤0.01% 1936
2018
Q1 		$1.21M Buy
+71,785
New +$1.09M ﹤0.01% 1856

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Wellington Management Group's IOVA Position: Q2 2026 in Review

Wellington Management Group opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 127,740 shares worth $531K. The stake represents ﹤0.01% of the portfolio and ranks #1824 among its holdings. This is a return to the name: Wellington Management Group previously reported a position in IOVA as recently as Q1 2025.

Wellington Management Group first reported a position in IOVA in Q1 2018 and has held it in 27 quarters since. The position peaked at $260M in Q4 2020. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Wellington Management Group held 127,740 shares of Iovance Biotherapeutics worth $531K as of Q2 2026.
  • Iovance Biotherapeutics was a new Wellington Management Group position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1824 holding.
  • Wellington Management Group first reported a position in Iovance Biotherapeutics in Q1 2018 and has held it in 27 quarters since.
  • Wellington Management Group's Iovance Biotherapeutics position peaked at $260M in Q4 2020.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.